Ozempic (semaglutide) and Trulicity (dulaglutide) are prescription drugs used for people with type 2 diabetes and certain other conditions. Both drugs are injected under the skin. Ozempic and ...

The U.S. Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in ...

Trulicity (dulaglutide) is not a weight loss drug, but people receiving it may lose weight. Higher doses of Trulicity typically result in more weight loss. The FDA has not approved Trulicity as a ...

Once-weekly treatment for adults with type 2 diabetes comes in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 10, 2014 /PRNewswire/ -- The newest GLP-1 receptor agonist treatment option to ...

Mounjaro (tirzepatide) and Trulicity (dulaglutide) are prescription medications that help manage blood sugar levels in adults with type 2 diabetes. Though they work in slightly different ways, they ...

The labeling for Trulicity (dulaglutide; Eli Lilly) has been updated to include use in combination with basal insulin for adults with type 2 diabetes, following approval from the Food and Drug ...

hba1c hemoglobin diabetes test At Week 24, both dulaglutide 0.75mg and 1.5mg added to ongoing SGLT-2 inhibitor therapy showed statistically superior glycemic control (-1.21% and -1.34%, respectively) ...

NEW YORK - Many people looking to lose weight are turning to Ozempic and similar drugs. The issue is that those medicines are also used by people with diabetes. One Long Island man who has Type 2 ...

Eli Lilly on Sunday launched a DTC campaign for its injectable diabetes drug Trulicity as it seeks to build market share in the competitive GLP-1 receptor agonist class, which has four other approved ...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...